recent
year
increas
recognit
import
viral
infect
addit
new
antivir
agent
becom
avail
factor
led
mark
increas
util
viral
diagnositc
servic
review
convent
rapid
method
viral
diagnosi
present
emphasi
recent
advanc
antivir
agent
current
avail
major
drug
investig
also
briefli
discuss
hope
review
serv
use
adjunct
manag
patient
viru
infect
content
despit
preval
viral
infect
viral
diagnost
laboratori
tradit
exist
part
either
region
health
depart
univers
research
laboratori
convent
viral
diagnost
method
consid
timeconsum
expens
inaccess
practis
physician
herrmann
herrmann
herrmann
hsiung
thu
accur
viral
diagnosi
infrequ
attempt
howev
recent
year
import
viral
infect
increasingli
recogn
particularli
caus
morbid
mortal
immunosuppress
patient
muller
et
al
ho
shield
et
al
sever
subtl
diseas
neonat
stagno
et
al
whitley
et
al
well
caus
vener
diseas
ng
et
al
jordon
et
al
handsfield
et
al
epidem
acquir
immunodefici
syndrom
aid
focus
world
attent
virus
potenti
seriou
pathogen
barresinoussi
et
al
popov
et
al
shaw
et
al
addit
virus
may
etiolog
link
cancer
rawl
et
al
henl
et
al
hanto
et
al
andiman
et
al
durst
et
al
wongstaal
importantli
promis
new
antivir
agent
becom
avail
therapi
effect
must
institut
earli
cours
diseas
thu
increas
interest
viral
diagnosi
particularli
develop
rapid
diagnost
procedur
viral
infect
gardner
yolken
richman
et
al
b
awar
part
medic
commun
public
signific
herp
infect
particular
led
establish
viral
diagnost
laboratori
increas
number
commun
hospit
tremend
increas
util
viral
diagnost
servic
previous
avail
region
laboratori
univers
hospit
also
burgeon
commerci
laboratori
offer
viral
diagnost
test
hospit
practition
without
servic
readili
avail
number
commerci
compani
product
avail
aid
viral
diagnosi
also
greatli
increas
advent
antivir
therapi
longer
accept
lack
accur
viral
diagnosi
hinder
delay
treatment
patient
thu
physician
begin
demand
laboratori
diagnosi
patient
ill
order
specif
proper
treatment
accomplish
viral
diagnost
facil
becom
access
addit
health
practition
must
knowledg
regard
procedur
use
viral
diagnosi
purpos
review
therefor
discuss
new
standard
method
viru
recognit
identif
special
refer
rapid
diagnosi
advanc
made
last
year
select
antivir
agent
current
use
also
briefli
discuss
hope
review
serv
use
adjunct
manag
patient
viru
infect
convent
method
viral
diagnosi
consist
viru
isol
serolog
light
electron
microscopi
perform
certain
situat
although
tremend
interest
develop
rapid
diagnost
techniqu
convent
diagnost
method
remain
wide
use
essenti
confirm
use
newer
techniqu
howev
must
emphas
standard
viru
isol
electron
microscopi
allow
success
recognit
unexpect
new
virus
critic
first
step
make
success
viral
diagnosi
obtain
proper
specimen
includ
choic
specimen
proper
collect
transport
initi
step
appropri
undertaken
subsequ
time
effort
spent
attempt
viru
isol
wast
choic
specimen
depend
upon
clinic
syndrom
virus
suspect
sinc
one
syndrom
associ
mani
virus
set
specimen
often
recommend
gener
specimen
viru
isol
collect
earli
ill
mani
virus
excret
day
howev
certain
virus
cytomegaloviru
cmv
enterovirus
adenovirus
excret
prolong
period
tabl
contain
commonli
encount
clinic
syndrom
associ
virus
appropri
specimen
obtain
throat
swab
vigor
swab
posterior
pharynx
visibl
lesion
obtain
stool
specimen
prefer
rectal
swab
larger
sampl
size
result
greater
yield
viru
isol
firstvoid
morn
urin
best
two
three
specimen
optim
cmv
isol
aspir
nasopharyng
mucu
found
superior
nasal
swab
nasal
wash
isol
respiratori
syncyti
viru
rsv
bromberg
et
al
bronchoalveolar
lavag
specimen
found
superior
bronchial
wash
cmv
stover
et
al
martin
smith
sinc
virus
oblig
intracellular
organ
requir
live
cell
replic
result
signific
decreas
viru
infect
titer
occur
clinic
specimen
allow
stand
period
room
temperatur
best
result
direct
inocul
cell
cultur
bedsid
done
gener
feasibl
therefor
swab
tissu
place
viral
transport
media
contain
balanc
salt
solut
protein
stabil
gelatin
calf
serum
varieti
collect
throat
swab
stool
csft
acut
convalesc
sera
collect
case
tcerebrospin
fluid
transport
devic
avail
commerci
subject
sever
recent
studi
johnson
et
al
warford
et
al
urin
stool
spinal
fluid
bodi
fluid
place
steril
contain
prompt
transport
laboratori
imper
delay
necessari
specimen
held
inocul
cell
cultur
long
delay
necessari
specimen
frozen
transport
distant
laboratori
specimen
ship
rapid
deliveri
servic
wet
ice
frozen
sampl
ship
dri
ice
swab
dri
specimen
left
room
temperatur
period
viru
infect
deterior
markedli
serum
usual
obtain
serodiagnosi
help
viru
isol
confirm
unusu
isol
whole
blood
leukocyt
also
use
viru
isol
eg
cmv
epsteinbarr
viru
specimen
arriv
laboratori
must
inocul
promptli
sensit
test
system
sinc
virus
requir
live
cell
replic
inocul
cell
cultur
laboratori
anim
necessari
unfortun
singl
cultur
system
support
growth
virus
thu
varieti
cell
cultur
routin
use
diagnost
laboratori
certain
circumst
embryon
egg
small
anim
may
util
appar
laboratori
personnel
must
know
clinic
syndrom
andor
virus
suspect
order
choos
appropri
system
insensit
system
util
unlik
viru
isol
even
though
viru
present
specimen
discoveri
polioviru
could
replic
nonneur
tissu
cultur
ender
et
al
revolution
diagnost
virolog
current
cell
cultur
mainstay
viral
diagnost
laboratori
mani
lab
system
employ
embryon
egg
small
anim
serolog
reserv
larger
refer
laboratori
prolifer
type
cell
cultur
avail
gener
three
main
type
cell
cultur
use
primari
cell
cultur
diploid
cell
strain
continu
cell
line
primari
cell
cultur
made
directli
anim
human
tissu
subpassag
time
diploid
cell
strain
gener
deriv
human
embryon
tissu
particularli
embryon
lung
subcultur
passag
continu
cell
line
usual
deriv
human
anim
tumor
propag
indefinit
wide
varieti
primari
cell
cultur
eg
monkey
kidney
rabbit
kidney
human
diploid
fibroblast
hdf
cell
strain
eg
continu
cell
line
eg
hela
avail
commerci
choic
type
cell
cultur
employ
laboratori
depend
upon
virus
sought
patient
popul
econom
constraint
fairli
broad
spectrum
virus
cultur
one
set
follow
cell
cultur
use
primari
monkey
kidney
mk
hdf
cell
use
sever
cell
type
facilit
chanc
recov
varieti
viru
type
clinic
specimen
inocul
cell
cultur
presenc
viru
may
detect
sever
way
commonli
virusinduc
chang
round
refractil
cell
grapelik
cluster
note
fig
ch
chang
call
cytopath
effect
cpe
vari
depend
caus
viru
format
syncytia
characterist
certain
virus
respiratori
syncyti
viru
measl
well
parainfluenza
type
inocul
continu
cell
line
fig
j
virus
produc
visibl
chang
therefor
indirect
test
presenc
necessari
influenza
parainfluenza
virus
hemadsorpt
test
util
wherebi
dilut
solut
guineapig
red
blood
cell
ad
infect
monolay
cell
allow
adsorb
wash
influenza
parainfluenza
present
red
cell
adher
infect
cell
monolay
fig
rubella
viru
interfer
test
tradit
use
method
cell
cultur
infect
suspect
rubella
viru
superinfect
echoviru
viru
readili
produc
cpe
presenc
rubella
howev
expect
virusinduc
cpe
develop
interf
speed
appear
progress
cpe
also
help
distinguish
virus
howev
also
depend
upon
concentr
viru
inoculum
sensit
particular
cell
cultur
use
preliminari
identif
viru
isol
made
base
upon
type
cell
cultur
viru
grow
charact
virusinduc
cellular
chang
exampl
cytomegaloviru
induc
cpe
human
fibroblast
cell
wherea
herp
simplex
viru
hsv
induc
cpe
human
fibroblast
rabbit
kidney
rk
cell
fig
final
identif
usual
requir
neutral
test
use
typespecif
antiserum
howev
mani
laboratori
rapid
method
identif
appli
immunofluoresc
monoclon
antibodi
see
section
sever
report
demonstr
feasibl
use
mini
satellit
laboratori
whose
servic
tailor
facil
laboratori
need
patient
popul
serv
herrmann
herrmann
peterson
et
al
landri
hsiung
exampl
cost
viru
isol
significantli
reduc
use
microtit
plate
contain
differ
type
cell
cultur
viru
isol
use
latter
system
compar
favor
standard
techniqu
herrmann
herrmann
peterson
et
al
report
advantag
use
satellit
laboratori
time
report
result
reduc
primari
viru
isol
perform
local
small
hospitalbas
laboratori
compar
send
specimen
statewid
refer
laboratori
number
viru
isol
satellit
laboratori
slightli
greater
refer
laboratori
cost
compar
routin
bacteriolog
specimen
laboratori
natur
patient
popul
hsv
frequent
encount
sensit
cell
system
appear
nonprim
cell
ie
rabbit
kidney
guineapig
embryo
gpe
cell
landri
et
al
hsiung
et
al
sinc
human
virus
gener
grow
well
nonprim
cell
presumpt
identif
made
accord
cell
suscept
characterist
cpe
shown
tabl
hsv
induc
characterist
cpe
human
diploid
fibroblast
rk
cell
cytomegaloviru
varicellazost
viru
vzv
replic
human
fibroblast
enterovirus
grow
best
primari
mk
vherea
adenovirus
advantag
taken
select
cellcultur
system
presumpt
identif
enterovirus
hsiung
hsiung
landri
et
al
recent
type
hsv
type
nordlund
et
al
produc
plaqu
gpe
chick
embryo
ce
cell
cultur
wherea
induc
plaqu
gpe
cell
ce
cell
two
viru
type
easili
identifi
two
cell
system
use
howev
typespecif
monoclon
antibodi
avail
rapid
accur
select
cell
system
balkov
hsiung
virus
identifi
cell
suscept
characterist
cpe
refer
larger
refer
laboratori
final
identif
although
number
commun
hospit
virolog
laboratori
increas
yearli
major
still
inhous
viral
cultur
avail
therefor
accur
viral
diagnosi
made
specimen
must
sent
refer
laboratori
commerci
laboratori
viru
isol
readi
avail
overnight
rapid
deliveri
servic
specimen
process
promptli
result
compar
inhous
process
ray
minnich
addit
new
specimen
transport
devic
use
human
fibroblast
cell
cultur
viru
may
replic
transport
warford
et
al
increas
util
viru
isol
come
demand
improv
isol
rate
rapid
result
therefor
common
diagnost
procedur
reevalu
attempt
optim
collect
transport
specimen
specimen
process
condit
cultur
incub
select
sensit
cell
cultur
system
viru
differ
process
method
examin
determin
optimum
detect
enteroviru
viremia
prather
et
al
factor
influenc
recoveri
varicellazost
viru
vzv
also
studi
levin
et
al
number
studi
determin
import
centrifug
specimen
onto
monolay
improv
isol
rate
rapid
result
hsv
cmv
report
gleav
et
al
gleav
et
al
salmon
et
al
fraction
semen
inocul
pellet
fraction
cultur
associ
elimin
monolay
toxic
enhanc
cmv
detect
aid
patient
howel
et
al
continu
search
better
cultur
system
viru
remain
import
task
diagnost
virologist
recent
report
indic
mink
lung
cell
line
highli
sensit
infect
hsv
fayram
et
al
smith
et
al
anoth
studi
cell
found
sensit
cmv
isol
gregori
menegu
incub
temperatur
long
recogn
import
isol
respiratori
virus
optim
recent
report
use
isol
cytomegaloviru
cmv
result
doubl
isol
rate
rapid
onset
cmv
cpe
averag
day
gregori
menegu
perhap
import
develop
viru
isol
cultiv
sever
virus
previous
consid
amen
isol
cell
cultur
hepat
viru
hav
isol
directli
fecal
extract
sever
cell
cultur
type
provost
et
al
daemer
et
al
siegl
et
al
sinc
viru
cytopath
immunolog
assay
radioimmunoassay
ria
necessari
detect
presenc
human
rotaviru
abl
cultiv
cell
cultur
trypsin
ad
media
success
isol
propag
sever
differ
cell
cultur
graham
est
naguib
et
al
reliabl
method
detect
identif
rotaviru
cultur
sever
enter
adenovirus
first
detect
electron
microscopi
consid
fastidi
isol
propag
sever
cell
system
cell
consid
sensit
brown
et
al
abil
isol
virus
cell
cultur
greatli
facilit
studi
virus
allow
antigen
product
make
way
develop
vaccin
howev
diagnost
use
methodolog
serolog
detect
hav
igm
antibodi
elisa
detect
rotaviru
antigen
remain
method
choic
initi
isol
human
immunodefici
viru
hiv
discoveri
central
identif
caus
agent
aid
develop
simpler
screen
test
viru
barresinoussi
et
al
gallo
et
al
levi
et
al
mainstay
diagnosi
human
immunodefici
viru
hiv
detect
viral
antibodi
elisa
posit
serum
sampl
retest
supplementari
test
western
blot
radioimmunoprecipit
schupbach
et
al
howev
detect
viral
antibodi
alon
determin
whether
individu
current
infect
viru
addit
antibodi
may
develop
six
twelv
month
infect
may
becom
undetect
late
cours
aid
isol
viru
infect
individu
serv
purpos
howev
remain
elabor
labor
intens
lengthi
process
current
perform
primarili
special
research
center
procedur
isol
recent
review
elsewher
schupbach
et
al
griffith
fig
briefli
human
mononuclear
cell
separ
peripher
blood
normal
donor
suspend
growth
media
contain
mitogen
phytohemagglutinin
tcell
growth
factor
interleukin
sever
day
lymphocyt
cultur
initi
patient
specimen
inocul
observ
week
viral
cytopath
effect
fig
supernat
assay
weekli
product
viral
replic
revers
transcriptas
viral
antigen
freshli
prepar
stimul
lymphocyt
cultur
ad
week
although
continu
cell
line
avail
support
growth
hiv
line
sensit
primari
lymphocyt
cultur
isol
viru
patient
specimen
continu
cell
line
advantag
howev
show
littl
cpe
produc
larg
amount
viru
thu
essenti
product
viral
antigen
diagnost
test
human
although
isol
hiv
current
tediou
expens
routin
diagnost
use
anticip
methodolog
improv
certainli
play
larger
role
futur
preliminari
identif
viru
isol
cpe
cell
cultur
final
identif
requir
laborintens
neutral
hemagglutin
inhibit
complement
fixat
test
despit
time
invest
result
test
alway
clearcut
addit
increas
import
viral
diagnosi
patient
care
rapid
specif
identif
need
mistak
delay
identif
advers
affect
treatment
patient
manag
recent
year
number
tool
molecular
geneticist
use
identif
fingerprint
rna
dna
virus
oligonucleotid
map
polyacrylamid
gel
electrophoresi
viral
protein
use
determin
genet
epidemiolog
relationship
poliovirus
use
determin
relat
case
paralyt
polio
vaccin
strain
polio
minor
nottay
et
al
oligonucleotid
map
also
use
studi
evolut
influenza
viru
strain
natur
nakajima
et
al
nakajima
et
al
young
pales
electropherotyp
human
rotaviru
strain
use
identifi
strain
involv
diseas
outbreak
within
hospit
set
differ
part
world
albert
et
al
chiba
et
al
rodger
et
al
rodriguez
et
al
spencer
et
al
techniqu
use
confirm
differ
rotaviru
strain
isol
china
previous
recogn
rotaviru
strain
hung
et
al
recent
year
restrict
enzym
analysi
use
identifi
classifi
dna
virus
herp
adenoand
papovaviru
group
techniqu
viral
dna
incub
specif
endonucleas
result
cleavag
suscept
dna
sequenc
fragment
separ
gel
electrophoresi
characterist
fingerprint
viru
obtain
summer
applic
restrict
endonucleas
analysi
particularli
use
studi
hsv
readili
distinguish
techniqu
consid
gold
standard
type
isol
mayo
et
al
addit
strainspecif
differ
evid
allow
subclassif
isol
within
hsv
type
fig
result
restrict
endonucleas
analysi
prove
use
type
isol
larg
scale
lonsdal
trace
nosocomi
outbreak
hsv
linneman
et
al
dispel
concern
cluster
case
herp
enceph
due
circul
singl
neurovirul
strain
viru
landri
et
al
methodolog
appli
trace
sourc
cmv
infect
wilfert
et
al
yow
et
al
handsfield
et
al
well
studi
molecular
epidemiolog
vzv
martin
et
al
adenovirus
kemp
et
al
wadel
et
al
restrict
enzym
analysi
also
shown
reliabl
specif
neutral
hemagglutin
test
identif
adenovirus
fife
et
al
b
hammond
et
al
thu
restrict
endonucleas
fingerprint
provid
use
addit
method
viru
identif
direct
smear
skin
lesion
long
use
rapid
diagnosi
hsv
vzv
poxviru
infect
hsv
vzv
induc
multinucl
cell
characterist
intranuclear
inclus
cowdri
type
wherea
poxviru
infect
induc
typic
cytoplasm
inclus
guarnieri
bodi
infect
cell
viral
cultur
facil
avail
pap
smear
also
use
detect
presenc
hsv
infect
cervix
characterist
cmvinduc
intranuclear
inclus
pap
smear
infect
tissu
use
marker
diagnosi
cmv
infect
certain
viru
infect
cellular
chang
affect
organ
suffici
characterist
permit
presumpt
diagnosi
exampl
spongiform
degener
brain
patient
creutzfeldjacob
diseas
gibb
gajdusek
balloon
degener
liver
cell
seen
viral
hepat
ishak
recent
commerci
avail
highqual
immunolog
stain
reagent
nonradioact
label
viral
probe
situ
hybrid
allow
specif
sensit
diagnosi
viral
infect
made
use
tissu
section
routin
patholog
laboratori
see
section
electron
microscop
em
use
diagnosi
viral
diseas
sever
decad
method
viru
directli
visual
viru
size
shape
easili
identifi
fig
howev
differ
virus
morpholog
distinguish
routin
examin
eg
smallpox
vaccinia
hsv
vzv
em
techniqu
commonli
use
includ
neg
stain
viru
particl
electrondens
salt
phosphotungst
acid
fig
top
row
prepar
uitrathin
section
cell
tissu
suspect
harbor
viru
fig
middl
row
clinic
specimen
virusinfect
cultur
fluid
examin
directli
use
neg
stain
techniqu
thu
provid
rapid
diagnosi
viru
infect
hsiung
et
al
howev
difficulti
encount
number
viru
particl
sampl
examin
low
number
techniqu
develop
enhanc
viru
visual
includ
pseudoreplica
techniqu
smith
melnick
agar
gel
diffus
anderson
doan
ultracentrifug
smith
gehl
although
thin
section
tissu
usual
requir
day
specimen
prepar
em
reliabl
diagnosi
may
result
sinc
fine
structur
viru
particl
cell
like
preserv
may
especi
import
case
viru
particl
may
present
determin
locat
viru
particl
recognit
human
papovaviru
brain
cell
patient
progress
multifoc
leukoencephalopathi
zurhein
chou
identif
epsteinbarr
viru
cultur
lymphoblast
cell
deriv
burkitt
lymphoma
patient
epstein
et
al
would
miss
em
techniqu
use
applic
em
techniqu
uncov
number
new
virus
could
isol
cultur
includ
hepat
b
viru
dane
et
al
enter
adenovirus
stool
children
gastroenter
flewett
et
al
use
immun
electron
microscopi
iem
hepat
feinston
et
al
rotaviru
flewett
et
al
norwalk
agent
kapikian
et
al
first
visual
stool
content
iem
involv
mix
patient
specimen
immun
serum
result
aggreg
viral
particl
render
readili
visibl
also
use
rapid
diagnosi
respiratori
virus
clinic
specimen
doan
et
al
jonca
et
al
recent
innov
includ
develop
solidphas
iem
use
protein
found
time
sensit
em
time
sensit
elisa
detect
rotaviru
stool
svensson
et
al
anoth
modif
use
solidphas
iem
doubleantibodi
techniqu
formvar
carbonco
grid
treat
dilut
antibodi
result
approxim
increas
viru
particl
view
viru
facilit
addit
second
decor
antibodi
use
success
detect
papovavirus
giraldo
et
al
howev
despit
mani
contribut
em
iem
viru
diagnosi
still
expens
cumbersom
routin
applic
averag
diagnost
laboratori
rapid
isol
viru
accomplish
variabl
depend
upon
viru
type
amount
viru
clinic
specimen
sensit
cultur
system
util
certain
virus
hsv
often
isol
within
hr
inocul
cell
cultur
wherea
virus
requir
day
isol
amen
cultur
routin
employ
method
delay
encount
diagnosi
mani
common
viru
diseas
sourc
frustrat
physician
laboratori
personnel
advent
antivir
chemotherapi
dilemma
becom
acut
order
benefici
effect
outcom
ill
therapi
must
institut
earli
led
tremend
interest
develop
socal
rapid
viral
diagnost
method
format
european
pan
american
group
rapid
viral
diagnosi
regular
symposia
keep
member
abreast
recent
advanc
field
direct
result
interest
mclntosh
et
al
mclntosh
et
al
richman
et
al
b
ideal
rapid
diagnost
method
capabl
yield
result
within
hour
patient
admiss
hospit
test
perform
directli
clinic
materi
howev
test
result
obtain
within
day
admiss
would
render
viral
diagnost
method
compar
routin
use
microbiolog
laboratori
rapid
techniqu
would
includ
use
identifi
viral
antigen
nucleic
acid
directli
clinic
specimen
amplif
viru
cell
cultur
cellular
chang
occur
case
chang
occur
mani
techniqu
discuss
section
immunolog
basi
ie
depend
upon
specif
reaction
antigen
antibodi
reaction
must
label
marker
render
detect
marker
fluoresc
dye
radioisotop
enzym
peroxidas
import
develop
lead
increas
util
immunolog
detect
techniqu
includ
avail
highqual
commerci
reagent
includ
monoclonai
antibodi
anoth
signific
recent
chang
field
rapid
viral
diagnosi
introduct
nucleic
acid
hybrid
technolog
field
clinic
virolog
recent
advanc
allow
applic
techniqu
includ
first
molecular
clone
result
product
wellcharacter
specif
reagent
use
probe
second
recognit
abil
nucleic
acid
bind
nitrocellulos
allow
screen
larg
number
sampl
third
develop
nonradioact
biotinyl
probe
suitabl
use
clinic
laboratori
hybrid
techniqu
clinic
diagnosi
remain
experiment
time
howev
owe
tremend
interest
exist
area
prolifer
studi
publish
last
year
overview
present
immunolog
hybrid
techniqu
review
term
applic
direct
detect
viral
antigen
genom
clinic
specimen
detect
viru
infect
amplif
cell
cultur
gener
virus
replic
well
cell
cultur
direct
detect
method
ae
less
sensit
though
rapid
viru
isol
howev
applic
method
infect
cell
cultur
significantli
shorten
time
report
posit
result
addit
confirm
identif
viru
must
emphas
howev
techniqu
discuss
section
direct
specif
virus
suspect
open
mind
viru
isol
em
lead
discoveri
unsuspect
new
viral
agent
immunofluoresc
techniqu
includ
direct
fluoresc
antibodi
fa
procedur
indirect
fluoresc
antibodi
ifa
procedur
long
use
diagnosi
viral
diseas
first
introduc
develop
specif
detect
antigen
anim
tissu
coon
et
al
techniqu
specif
antibodi
tag
fluoresc
dye
allow
react
antigen
short
incub
site
antigenantibodi
reaction
visual
use
microscop
uv
light
sourc
direct
use
detect
antigen
util
specif
antibodi
conjug
directli
fluoresc
dye
quicker
simpler
exhibit
less
nonspecif
stain
indirect
method
indirect
method
util
specif
antibodi
conjug
allow
react
test
antigen
conjug
antibodi
ad
direct
anim
speci
primari
antibodi
made
test
use
detect
antigen
antibodi
advantag
requir
singl
conjug
detect
mani
antigenantibodi
reaction
provid
antisera
made
singl
speci
although
indirect
test
slightli
sensit
also
give
nonspecif
result
mani
difficulti
encount
sinc
introduct
techniqu
recent
year
mani
problem
overcom
exampl
adequ
number
infect
respiratori
epitheli
cell
essenti
respiratori
specimen
necessari
see
label
intracellular
antigen
distribut
intranuclear
intracytoplasm
cell
type
expect
particular
viru
also
experi
requir
distinguish
nonspecif
fluoresc
seen
bacteria
fungi
mucu
commonli
present
respiratori
specimen
proper
specimen
collect
sampl
prepar
import
minim
problem
skin
lesion
littl
problem
vesicular
stage
lesion
becom
crust
nonspecif
fluoresc
becom
problem
brain
biopsi
nonspecif
fluoresc
usual
problemat
autopsi
specimen
bacteri
overgrowth
occur
experi
requir
distinguish
nonspecif
fluoresc
gardner
owe
difficulti
obtain
specif
sensit
antisera
difficult
reproduc
result
outsid
research
set
avail
qualiti
reagent
demand
rapid
diagnosi
contribut
chang
first
appli
direct
detect
viru
clinic
specimen
identif
influenza
nasal
smear
liu
subsequ
rabi
detect
mous
brain
util
techniqu
quickli
becam
method
choic
rapid
diagnosi
rabi
viru
infect
goldwass
kissl
addit
use
detect
hsv
skin
lesion
biegeleisen
et
al
recent
appli
detect
number
virus
includ
hsv
schmidt
et
al
schmidt
et
al
vzv
schmidt
et
al
rsv
parainfluenza
wong
et
al
waner
et
al
clinic
specimen
vari
result
also
delta
hepat
viru
hdv
detect
liver
cell
nuclei
serum
hepat
b
viru
hbv
carrier
rizzetto
et
al
applic
use
monoclon
antibodi
direct
detect
influenza
shalit
et
al
cmv
martin
smith
clinic
specimen
produc
promis
result
perhap
rsv
gener
greatest
enthusiasm
due
difficulti
encount
cultur
benefit
rapid
diagnosi
avail
ribavirin
treatment
lauer
numer
investig
found
examin
nasopharyng
aspir
use
either
polyclon
monoclon
antibodi
sensit
cultur
cheeseman
et
al
freymuth
et
al
swenson
kaplan
advantag
immunofluoresc
procedur
perform
directli
clinic
specimen
includ
speed
simplic
low
cost
abil
make
diagnosi
convalesc
viral
infect
viru
render
noninfecti
presenc
antibodi
still
visibl
fluoresc
abil
make
diagnosi
specimen
delay
arriv
laboratori
great
advantag
howev
highli
depend
proper
collect
specimen
even
studi
condit
signific
percentag
specimen
unaccept
due
inadequ
number
epitheli
cell
make
specimen
untest
techniqu
also
first
use
year
ago
rapid
detect
identif
virus
amplif
cell
cultur
exampl
includ
rapid
detect
identif
measl
cohen
et
al
vzv
weller
coon
polioviru
kalter
et
al
subsequ
rubella
schmidt
et
al
applic
number
excit
potenti
use
innov
within
last
two
three
year
one
group
use
centrifug
specimen
onto
monolay
shell
vial
follow
applic
hr
gleav
et
al
hr
post
inocul
gleav
et
al
rapid
detect
cmv
urin
cmv
isol
detect
hr
respect
wherea
averag
day
requir
detect
cmv
cpe
use
standard
viru
isol
without
centrifug
stain
bal
blood
specimen
test
cmv
techniqu
fals
neg
result
obtain
paya
et
al
also
import
inocul
two
blood
sampl
three
shell
vial
per
specimen
optim
result
paya
et
al
methodolog
appli
earli
detect
hsv
excel
result
gleav
et
al
centrifug
shown
import
earli
detect
howev
methodolog
appli
rapid
detect
influenza
viru
use
monoclon
antibodi
influenza
isol
detect
hr
post
inocul
compar
averag
day
convent
isol
espi
et
al
anoth
studi
compar
short
term
hr
tissu
cultur
follow
standard
viru
isol
found
complet
agreement
two
method
howev
reagent
appli
directli
clinic
specimen
falseneg
falseposit
result
obtain
nerurkar
et
al
immunoperoxidas
ip
techniqu
follow
principl
techniqu
howev
conjug
enzym
often
horseradish
peroxidas
enzym
coupl
specif
antibodi
direct
method
antianim
speci
globulin
indirect
test
presenc
enzym
conjug
bound
virusinfect
cell
detect
ad
substrat
diaminobenzidin
aminoethylcarbazol
oxid
presenc
hydrogen
peroxid
result
reddishbrown
color
perman
test
potenti
applic
number
advantag
reaction
detect
nake
eye
light
microscop
import
laboratori
limit
budget
mani
product
electron
dens
thu
visual
electron
microscop
prepar
perman
reagent
readili
standard
stabl
less
nonspecif
reaction
ip
success
process
tissu
howev
procedur
first
describ
earli
avramea
ternynck
experi
much
less
extens
major
problem
endogen
peroxidas
present
leukocyt
clinic
specimen
especi
respiratori
tract
lead
nonspecif
stain
techniqu
develop
remov
endogen
peroxidas
strau
weir
et
al
also
result
remov
unstabl
viru
antigen
small
amount
viru
present
falseneg
result
obtain
applic
ip
techniqu
clinic
materi
includ
identif
rabi
atanasiu
hsv
varieti
clinic
specimen
morisset
et
al
schmidt
et
al
includ
brain
tissu
benjamin
ray
measl
brain
patient
sspe
brown
thormar
hepat
b
fix
liver
section
burn
also
compar
detect
influenza
respiratori
syncyti
viru
rsv
respiratori
specimen
gardner
et
al
two
techniqu
excel
agreement
remov
endogen
peroxidas
signific
problem
specimen
contain
rsv
remov
peroxidas
result
loss
rsv
antigen
recent
modif
result
sensit
assay
includ
peroxidaseantiperoxidas
pap
sternberg
joseph
avidinbiotin
complex
abc
techniqu
hsu
et
al
ip
method
use
earli
detect
viral
antigen
cell
cultur
obtain
rapid
diagnosi
benjamin
ray
purpos
receiv
much
wider
applic
recent
ip
use
identifi
rubella
isol
cell
cultur
schmidt
et
al
importantli
commerci
kit
hsv
cultiv
identif
develop
use
vero
cell
cultur
follow
hr
stain
pap
techniqu
although
kit
provid
valuabl
introduct
viru
isol
laboratori
without
virolog
expertis
see
fig
numer
studi
found
sensit
standard
viru
isol
sensit
kit
rang
compar
standard
tissu
cultur
fayram
et
al
hayden
et
al
rubin
roger
sewel
et
al
howev
problem
may
well
lie
kit
use
vero
cell
fairli
insensit
hsv
infect
compar
wide
use
hdf
primari
rk
cell
worker
use
hdf
cell
cultur
follow
ip
stain
hr
hsv
isol
detect
hr
ip
stain
eventu
detect
standard
cultur
miller
howel
addit
studi
demonstr
possibl
significantli
shorten
time
involv
maintain
observ
cell
cultur
applic
pap
techniqu
earli
detect
hsv
hdf
cell
cultur
specimen
process
hsv
essenti
cultur
posit
hsv
detect
hr
twothird
hr
pap
stain
result
signific
save
time
materi
mayo
et
al
combin
centrifug
specimen
onto
cell
monolay
follow
overnight
incub
ip
stain
found
sensit
well
rapid
standard
cell
cultur
diagnosi
hsv
salmon
et
al
thu
techniqu
much
potenti
rapid
viral
diagnosi
especi
laboratori
without
fluoresc
microscop
engval
perlmann
introduc
enzymelink
immunosorb
assay
elisa
quantit
rabbit
igg
engval
perlmann
techniqu
sensit
radioimmunoassay
ria
mani
advantag
ria
elisa
similar
ria
except
enzym
use
immunoglobulin
marker
instead
radioact
isotop
substrat
ad
enzymelabel
immunoglobulin
visibl
color
reaction
occur
read
visual
quantit
use
spectrophotomet
elisa
use
either
detect
antigen
antibodi
sever
variat
model
ria
detect
antigen
either
antibodi
sandwich
competit
assay
use
antibodi
sandwich
method
specif
antibodi
antigen
detect
use
coat
surfac
solid
phase
support
polystyren
bead
microtit
plate
test
tube
etc
test
sampl
eg
stool
bodi
fluid
ad
allow
react
direct
singl
antibodi
sandwich
test
enzym
conjug
specif
antibodi
ad
allow
react
indirect
doubleantibodi
sandwich
test
unlabeu
specif
antibodi
first
ad
enzym
conjug
antiglobulin
ad
final
step
amount
enzym
bound
detect
addit
substrat
intens
subsequ
color
reaction
proport
amount
antigen
test
sampl
competit
assay
specif
antibodi
adsorb
solid
phase
test
specimen
ad
addit
known
amount
label
antigen
unlabel
antigen
test
specimen
compet
label
antigen
antibodi
bind
site
substrat
ad
bound
enzym
result
color
chang
less
antigen
contain
materi
amount
antigen
test
sampl
determin
quantit
compar
color
obtain
known
standard
two
enzym
wide
use
elisa
horseradish
peroxidas
avramea
ternynck
alkalin
phosphatas
engval
perlmann
number
other
also
use
advantag
disadvantag
hosli
et
al
watanab
et
al
problem
elisa
similar
immunolog
test
puriti
sensit
specif
reagent
must
care
control
nonspecif
bind
problem
diminish
care
wash
addit
speci
specif
serum
reaction
mixtur
use
high
qualiti
specif
reagent
introduct
monoclon
antibodi
also
reduc
problem
addit
optim
condit
assay
vari
depend
antigen
enzym
substrat
etc
must
care
monitor
variabl
number
control
specimen
known
amount
antigen
alway
includ
everi
test
sinc
introduct
elisa
use
detect
varieti
antigen
antibodi
biolog
substanc
yolken
wide
appli
viral
antibodi
detect
great
success
notabl
hepat
b
viru
supplant
ria
human
immunodefici
viru
hiv
elisa
also
use
detect
viral
antigen
virus
difficult
propag
cultur
group
coxsackievirus
yolken
torsch
human
coronavirus
macnaughton
et
al
enter
adenovirus
anderson
et
al
norwalk
agent
gari
et
al
hepat
mathieson
et
al
coulepi
et
al
elisa
detect
virus
remain
research
tool
sinc
suffici
demand
test
clinic
laboratori
date
elisa
especi
use
diagnosi
rotaviru
infect
yolken
et
al
elisa
kit
rotaviru
antigen
detect
avail
commerci
number
year
found
compar
em
cheung
et
al
rubenstein
miller
recent
modif
result
even
sensit
rotaviru
elisa
kit
doern
et
al
howev
group
b
rotavirus
recent
detect
china
hung
et
al
detect
current
commerci
elisa
kit
hepat
b
viru
yet
propag
cell
cultur
limit
laboratori
method
serolog
detect
hbv
antibodi
antigen
recent
hybrid
detect
viral
dna
test
least
six
serolog
marker
hbv
avail
commerci
determin
pattern
marker
individu
patient
help
establish
stage
diseas
infect
immun
statu
prognosi
patient
applic
interpret
test
review
detail
elsewher
cherneski
et
al
elisa
also
appli
detect
delta
viru
antigen
antibodi
serum
crivelli
et
al
shattock
morgan
buti
et
al
result
less
need
diagnost
liver
biopsi
patient
elisa
also
use
detect
number
routin
cultur
virus
clinic
specimen
rsv
hornsleth
et
al
mclntosh
et
al
freymuth
et
al
swenson
kaplan
influenza
adenoviru
harmon
pawlick
hsv
lesion
swab
morgan
smith
nerurkar
et
al
warford
et
al
hsv
cerebrospin
fluid
patient
enceph
coleman
et
al
use
direct
detect
hsv
clinic
specimen
elisa
suffici
sensit
compar
cell
cultur
result
sewel
horn
howev
appli
hsv
infect
cell
lysat
result
significantli
improv
morgan
smith
elisa
could
prove
use
rapid
earli
identif
hsv
larg
number
cultur
process
recent
innov
hsv
elisa
spin
amplif
techniqu
sampl
centrifug
onto
monolay
incub
day
cell
cultur
lyse
assay
elisa
hsv
antigen
test
found
highli
sensit
specif
michalski
et
al
signific
recent
applic
develop
elisa
detect
core
protein
aid
viru
hiv
higgin
et
al
mcdougal
et
al
although
current
techniqu
isol
hiv
sensit
antigen
detect
highli
special
beyond
capabl
routin
viral
diagnost
laboratori
elisa
use
detect
hiv
core
antigen
serum
cerebrospin
fluid
allain
et
al
presenc
hiv
antigen
blood
found
earli
two
week
infect
wherea
develop
hiv
antibodi
may
requir
six
month
antigenemia
declin
hiv
core
antibodi
also
found
preced
onset
aid
paul
et
al
direct
detect
viral
antigen
also
use
follow
patient
antivir
therapi
declin
core
antigen
serum
demonstr
patient
receiv
azidothymidin
azt
chaisson
et
al
avail
elisa
detect
hiv
antigen
therefor
could
provid
use
addit
diagnost
test
aid
viru
infect
advantag
elisa
includ
low
cost
less
special
equip
stabil
reagent
avoid
use
hazard
radioisotop
wide
applic
abil
autom
test
read
visual
greatest
potenti
test
larg
number
specimen
viru
ria
develop
first
appli
detect
insulin
level
plasma
yalow
berson
sinc
time
ria
util
detect
wide
varieti
biolog
substanc
clinic
chemistri
laboratori
combin
high
sensit
radioisotop
label
specif
broad
applic
antigenantibodi
reaction
addit
larg
number
specimen
readili
test
sensit
specif
also
depend
upon
qualiti
reagent
label
adher
rigid
test
procedur
direct
indirect
assay
use
ip
elisa
ria
util
detect
hepat
b
antibodi
sinc
lander
et
al
hepat
b
antigen
sinc
ling
overbi
howev
mani
laboratori
replac
elisa
besid
hepat
b
ria
use
detect
viral
antigen
infect
cell
gener
cell
cultur
hayashi
et
al
hayashi
et
al
joseph
et
al
laush
et
al
also
clinic
specimen
forghani
et
al
forghani
et
al
halonen
et
al
detect
viral
antibodi
local
antigen
within
cell
possibl
method
ria
less
nonspecif
reactiv
enzymat
method
sensit
could
use
detect
small
amount
antigen
clinic
specimen
howev
disadvantag
deterior
radioact
isotop
requir
new
reagent
standard
everi
month
hazard
associ
use
radioisotop
expens
equip
requir
limit
use
larg
center
owe
increas
concern
potenti
hazard
personnel
dispos
problem
associ
radioact
isotop
avail
altern
equal
sensit
util
ria
expect
decreas
past
year
use
simpl
latex
agglutin
test
detect
rotaviru
report
cevenini
et
al
haikala
et
al
sensit
specif
compar
favor
elisa
hugh
et
al
sambourg
et
al
doern
et
al
techniqu
latex
bead
sensit
specif
antigen
incub
immun
serum
specif
igg
case
rotaviru
test
perform
mix
clarifi
stool
suspens
sensit
latex
bead
short
incub
examin
macroscop
clump
agglutin
latex
bead
clump
occur
rotaviru
antigen
present
stool
test
sensit
detect
small
amount
antigen
rotaviru
gastroenter
larg
quantiti
antigen
usual
excret
test
sever
potenti
advantag
perform
unskil
personnel
rapid
rel
cheap
may
prove
use
screen
doctor
offic
develop
countri
latex
agglutin
also
appli
recent
detect
hsv
clinic
specimen
found
sensit
howev
sensit
specif
posit
identif
hsv
appear
viral
cpe
cell
cultur
ignotofski
et
al
nucleic
acid
hybrid
techniqu
recent
introduc
field
clinic
virolog
date
appli
studi
viral
pathogenesi
rapid
viral
diagnosi
use
clinic
specimen
landri
fong
principl
hybrid
simpl
natur
state
dna
molecul
made
two
strand
base
specif
link
hydrogen
bond
complementari
base
strand
bond
base
broken
heat
treatment
alkali
two
strand
dna
dissoci
denatur
howev
proper
condit
dissoci
strand
reassoci
complementari
partner
test
condit
label
singlestrand
nucleic
acid
probe
contain
specif
sequenc
sought
mix
denatur
dissoci
sampl
dna
rna
complementari
nucleic
acid
sequenc
present
sampl
label
probe
reanneal
sequenc
form
doublestrand
hybrid
contain
label
label
hybrid
detect
varieti
method
quantit
current
techniqu
larg
involv
hybrid
label
probe
nucleic
acid
immobil
solid
support
nitrocellulos
techniqu
wide
use
research
includ
studi
viral
pathogenesi
southern
blot
method
purifi
dna
sampl
first
cleav
restrict
endonucleas
fragment
separ
gel
electrophoresi
dna
transfer
gel
onto
nitrocellulos
filter
method
e
southern
southern
nitrocellulos
immers
hybrid
solut
contain
label
probe
adequ
time
elaps
reanneal
occur
nitrocellulos
filter
remov
solut
subject
seri
wash
vari
stringenc
remov
untreat
probe
unstabl
hybrid
bind
label
probe
confin
distinct
band
correspond
nucleic
acid
fragment
separ
electrophoresi
therefor
possibl
identifi
even
weak
signal
specif
detect
viral
nucleic
acid
clinic
specimen
wide
use
techniqu
date
spot
dotblot
method
nucleic
acid
cell
suspens
spot
directli
onto
nitrocellulos
filter
grid
pattern
without
suction
filtrat
obviou
advantag
speed
simplic
avoid
restrict
enzym
analysi
gel
electrophoresi
dna
transfer
requir
labori
extract
purif
dna
necessari
southern
blot
addit
larg
number
specimen
process
simultan
howev
sinc
visual
spot
identifi
utmost
import
guard
nonspecif
result
fals
posit
result
spot
hybrid
report
due
reaction
residu
bacteri
plasmid
vector
sequenc
probe
patient
sampl
dieguti
et
al
care
attent
stringenc
condit
probe
specif
posit
neg
control
essenti
spot
hybrid
use
detect
number
virus
clinic
specimen
appli
detect
less
readili
isol
virus
vzv
spot
hybrid
greater
sensit
cultur
cmv
time
detect
greatli
shorten
tissu
cultur
infecti
dose
per
ml
necessari
posit
result
chou
merigan
anoth
studi
spot
hybrid
found
sensit
cultur
detect
cmv
buffi
coat
spector
et
al
appli
virus
routin
isol
rotaviru
flore
et
al
enter
adenovirus
stalhandsk
et
al
stalhandsk
et
al
takiff
et
al
parvovirus
clewley
anderson
et
al
papovavirus
gibson
et
al
wickenden
et
al
epsteinbarr
viru
andiman
et
al
spot
hybrid
could
prove
use
detect
hbvdna
serum
spot
hybrid
correl
activ
viru
replic
carloni
et
al
hbvdna
detect
absenc
serolog
marker
hbv
infect
brechot
et
al
thu
provid
new
diagnost
tool
may
use
prognosi
therapi
bonino
et
al
hadziyanni
et
al
bonino
howev
techniqu
found
sensit
direct
detect
virus
readili
isol
cultur
enterovirus
hyypia
et
al
hsv
redfield
et
al
recent
report
modif
sandwich
hybrid
base
use
two
separ
nucleic
acid
fragment
one
attach
filter
label
nucleic
acid
sequenc
fragment
complementari
nucleic
acid
sought
sampl
two
reagent
sequenc
common
therefor
hybrid
thu
posit
sampl
attach
reagent
bound
filter
result
three
compon
dna
sandwich
mediat
attach
label
probe
filter
sinc
sampl
kept
solut
throughout
process
oppos
spot
onto
filter
compon
contain
crude
sampl
lipid
mucopolysaccharid
protein
etc
nonspecif
bind
nucleic
acid
fix
filter
allow
process
crude
sampl
assay
either
rna
dna
sandwich
method
sensit
spot
hybrid
ranki
et
al
virtanen
et
al
addit
use
label
report
date
disadvantag
clinic
laboratori
biotinyl
probe
use
spot
hybrid
hyypia
situ
hybrid
intact
cell
paraffin
embed
tissu
frozen
tissu
touch
prep
examin
viral
genom
brigati
et
al
forghani
et
al
beckmann
et
al
use
detect
cmv
lung
tissu
situ
hybrid
found
similar
sensit
cultur
monoclon
antibodi
sensit
routin
histolog
myerson
et
al
myerson
et
al
fig
situ
hybrid
proven
use
detect
human
papiuomaviru
hpv
genit
tract
tissu
hpv
yet
propag
cell
cultur
type
identifi
restrict
enzym
analysi
hybrid
studi
certain
type
type
commonli
associ
genit
wart
rare
associ
cervic
cancer
wherea
genit
infect
type
type
consid
high
risk
progress
malign
campion
et
al
crum
et
al
one
recent
report
detect
hpv
infect
clinic
specimen
found
situ
hybrid
radiolabel
probe
inferior
southern
blot
spot
hybrid
caussi
et
al
yet
other
found
situ
techniqu
biotinyl
probe
highli
sensit
beckmann
et
al
biotinyl
dna
probe
avail
commerci
distinguish
infect
type
infect
high
risk
type
impact
manag
patient
cervic
dysplasia
situ
hybrid
advantag
histolog
evalu
time
give
inform
local
sequenc
within
tissu
cell
type
infect
sensit
sequenc
present
concentr
one
area
howev
procedur
labor
intens
sampl
problem
addit
direct
detect
virus
clinic
specimen
recent
studi
also
appli
spot
hybrid
radioact
probe
detect
hsv
stalhandsk
fic
detect
cytomegaloviru
cmv
infect
cell
lung
tissu
use
situ
hybrid
biotinyl
cmv
dna
probe
situ
hybrid
perform
use
biotinyl
cmv
dna
probe
myerson
et
al
formalin
fix
paraffin
embed
lung
tissu
bone
marrow
transplant
patient
pneumonia
cmv
infect
ceil
render
readili
visibl
dark
nuclear
cytoplasm
stain
photograph
courtesi
dr
myerson
petterson
enterovirus
rotbart
et
al
cell
cultur
lysat
infect
titer
enterovirus
per
ml
lysat
necessari
posit
result
situ
hybrid
biotinyl
clone
dna
probe
compar
avidinbiotin
ip
stain
detect
hsv
infect
cell
two
differ
cell
system
ip
stain
found
sensit
landri
et
al
significantli
highli
sensit
cell
system
use
cpe
alon
compar
rapid
sensit
viral
antigen
dna
detect
method
appli
less
sensit
cell
system
knowledg
biolog
biochemistri
viral
function
increas
potenti
discoveri
new
specif
antivir
agent
increas
accordingli
current
need
accur
reliabl
diagnosi
viral
infect
great
extent
result
discoveri
avail
new
antivir
agent
although
beyond
scope
review
present
comprehens
report
antivir
chemotherapi
sever
current
avail
antivir
agent
promis
new
antivir
discuss
precis
mechan
action
compound
clear
although
earli
event
viru
penetr
uncoat
almost
certainli
involv
vitro
sever
virus
sensit
antivir
activ
amantadin
cyclic
primari
amin
influenza
type
particularli
sensit
inhibit
influenza
viru
replic
occur
gml
less
one
studi
use
plaqu
reduct
assay
report
clinic
isol
sensit
pgml
less
lamontagn
galasso
earli
anim
studi
demonstr
effect
amantadin
protect
anim
influenza
viru
infect
dose
mgkg
protect
mice
subsequ
influenza
challeng
protect
observ
drug
start
late
hr
infect
protect
afford
administ
hr
davi
et
al
amantadin
consid
effect
prophylact
therapeut
use
human
strain
influenza
virus
studi
demonstr
amantadin
approxim
effect
prevent
influenza
also
effect
treat
diseas
lamontagn
galasso
sign
symptom
diseas
disappear
rapidli
patient
receiv
drug
compar
placebo
group
also
decreas
durat
quantiti
viru
shed
treatment
group
sideeffect
primarili
central
nervou
system
symptom
occur
patient
recent
studi
demonstr
effect
amantadin
prophylaxi
influenza
pettersson
et
al
younkin
et
al
recommend
particularli
unvaccin
person
high
risk
idu
incorpor
viral
dna
place
thymidin
result
essenti
nonfunct
viral
dna
nucleotid
idu
may
also
interfer
variou
enzym
system
involv
viral
dna
synthesi
mechan
action
similar
halogen
deoxypyrimidin
nucleosid
bromodeoxyuridin
fluorodeoxyuridin
declercq
torrenc
concentr
idu
inhibit
replic
vaccinia
viru
effect
noninfect
cell
prusoff
goz
antiherpet
effect
idu
vivo
demonstr
rabbit
soon
discoveri
effect
cell
cultur
kaufman
control
studi
human
follow
quickli
confirm
idu
effect
treat
herp
keratoconjunct
burn
laibson
leopold
toxic
allerg
reaction
may
occur
prolong
use
idu
altern
therapi
may
therefor
necessari
mcgill
et
al
amon
et
al
iduresist
hsv
strain
occur
experiment
underwood
et
al
resist
mutant
isol
patient
hirano
et
al
idu
first
effect
antiherpet
drug
approv
human
use
howev
toxic
system
administr
effect
topic
skin
mucou
membran
trifluorothymidin
tft
exert
highest
antivir
activ
fluorin
pyrimidin
heidelberg
mechan
action
kalman
similar
ident
pyrimidin
nucleosid
analog
see
tft
specif
inhibit
herpesviru
replic
vitro
umeda
heidelberg
shown
effect
treatment
herp
simplex
viru
vaccinia
viru
kerat
rabbit
kaufman
heidelberg
clinic
trial
tft
treatment
herp
kerat
shown
least
effect
idu
adenin
arabinosid
araa
use
associ
fewer
sideeffect
one
trial
shown
tft
effect
idu
pavanlangston
foster
anoth
trial
compar
tft
araa
treatment
herpet
ameboid
ulcer
found
heal
tfttreat
ulcer
slightli
rapid
araatr
ulcer
howev
tft
also
toxic
system
administr
like
idu
use
limit
eye
infect
primari
mechan
action
adenin
arabinosid
araa
vidarabin
inhibit
dna
synthesi
inhibit
viru
dna
polymeras
incorpor
viral
dna
cellular
viral
dna
inhibit
occur
inhibit
cellular
dna
synthesi
less
mark
muller
et
al
cell
cultur
vidarabin
exhibit
broad
rang
antivir
activ
dna
virus
includ
hsv
vzv
human
cmv
well
anim
herpesvirus
poxvirus
shannon
topic
vidarabin
therapi
effect
treat
hsv
kerat
see
import
use
treatment
system
diseas
earli
studi
demonstr
efficaci
treatment
hsv
enceph
mice
sloan
et
al
similar
recent
studi
found
decreas
titer
hsv
brain
prolong
surviv
vidarabinetr
mice
griffith
et
al
topic
treatment
mice
inocul
cutan
hsv
reduc
mortal
decreas
establish
latenc
sensori
ganglia
vidarabinetr
mice
treatment
begun
soon
infect
klein
freidmankien
vidarabin
minim
effect
cmv
murin
model
overal
et
al
result
decreas
urinari
excret
human
studi
clinic
improv
appar
chien
et
al
treatment
vzv
infect
man
vidarabin
demonstr
antivir
effect
walden
et
al
encourag
result
util
vidarabin
come
studi
hsv
enceph
victim
result
collabor
enceph
studi
demonstr
efficaci
drug
mortal
due
biopsyproven
hsv
enceph
wherea
treatment
vidarabin
reduc
whitley
et
al
followup
studi
confirm
origin
observ
establish
age
level
conscious
start
therapi
two
import
factor
influenc
outcom
whitley
et
al
benefici
effect
vidarabin
treatment
neonat
hsv
infect
report
also
suggest
earli
institut
therapi
might
improv
outcom
diseas
whitley
et
al
increas
dose
drug
decreas
morbid
mortal
thu
vidarabin
first
drug
approv
system
use
seriou
herpesviru
infect
howev
absorb
well
topic
administr
acyclovir
acv
also
known
acycloguanosin
guanin
phosphoryl
herpesvirusinfect
cell
viruscod
enzym
thymidin
kinas
tk
result
acv
monophosph
phosphoryl
cellular
kinas
acv
triphosph
acv
triphosph
competit
inhibitor
viral
dna
polymeras
may
inhibit
viral
dna
synthesi
incorpor
dna
therebi
caus
termin
dna
chain
elion
et
al
vitro
acv
inhibit
hsv
varicellazost
epsteinbarr
virus
human
cmv
report
sensit
high
level
acv
vitro
clinic
isol
usual
resist
level
drug
attain
patient
crumpack
et
al
anim
hsv
experi
use
rabbit
pavanlangston
et
al
mice
mayo
et
al
hairless
mice
klein
et
al
guineapig
landri
et
al
demonstr
effect
low
toxic
acv
human
trial
follow
rapidli
one
studi
demonstr
effect
topic
acv
administr
ocular
diseas
anoth
uncontrol
studi
patient
neoplast
diseas
bone
marrow
transplant
note
improv
cutan
system
hsv
vzv
infect
selbi
et
al
random
doubleblind
studi
bone
marrow
transplant
recipi
demonstr
effect
intraven
administ
acv
prevent
appear
cultur
posit
hsv
lesion
acv
cure
latent
infect
evidenc
appear
hsv
lesion
cessat
therapi
saral
et
al
preliminari
report
compar
vidarabin
acv
treatment
neonat
hsv
infect
suggest
acv
least
effect
vidarabin
treatment
sever
infect
importantli
topic
treatment
human
primari
genit
hsv
lesion
acv
ointment
shorten
mean
durat
viru
shed
also
time
complet
crust
lesion
corey
et
al
addit
short
term
oral
therapi
primari
recurr
genit
hsv
infect
significantli
reduc
viru
shed
time
heal
lesion
nilsen
et
al
bryson
et
al
longterm
oral
therapi
prevent
recurr
genit
lesion
acvtreat
patient
long
therapi
maintain
howev
treatment
discontinu
recurr
rate
similar
placebotr
group
addit
acyclovir
report
effect
vidarabin
treatment
hsv
enceph
whitley
et
al
ribavirin
virazol
purin
analog
resembl
guanosin
wide
rang
activ
rna
dna
virus
drug
interfer
synthesi
guanosin
monophosph
result
inhibit
rna
dna
synthesi
influenza
virus
among
sensit
inhibit
sidwel
et
al
ribavirin
shown
inhibit
rsv
replic
vitro
hruska
et
al
anim
model
hruska
et
al
sever
doubleblind
studi
shown
aerosol
administr
ribavirin
infect
infant
result
rapid
improv
overal
sever
ill
increas
disappear
rsv
respiratori
secret
evid
intoler
toxic
treat
babi
taber
et
al
drug
approv
aerosol
treatment
infant
young
children
sever
lower
respiratori
infect
due
rsv
trisodium
salt
phosphonoform
pfa
inhibit
herpesviru
dna
polymeras
level
drug
appreci
affect
cellular
polymeras
cell
cultur
pfa
inhibit
herpesviru
replic
depend
viru
helgstrand
et
al
reno
et
al
larsson
oberg
mechan
action
phosphonoacet
paa
pfa
prefer
dermal
toxic
associ
topic
paa
applic
harri
boyd
aleniu
oberg
recent
vitro
studi
demonstr
greater
activ
pfa
use
combin
either
drug
use
alon
ayisi
et
al
anim
model
pfa
effect
treat
cutan
herp
guineapig
aleniu
oberg
herp
kerat
rabbit
aleniu
et
al
genit
herp
guineapig
aleniu
nordlind
latter
genit
herp
model
guineapig
treatment
effect
begun
within
hr
infect
recent
investig
found
pfa
treatment
also
effect
treatment
guineapig
genit
herp
begun
near
time
appear
symptom
lucia
et
al
doubleblind
control
studi
cutan
labial
herp
human
similarli
demonstr
benefici
effect
pfa
treatment
durat
hsvinduc
lesion
wallin
et
al
concern
howev
longterm
deposit
drug
bone
bromovinyldeoxyuridin
bvdu
nucleosid
analog
preferenti
incorpor
viral
dna
hsv
tk
involv
preferenti
incorpor
tk
mutant
hsvi
resist
effect
bvdu
although
activ
vitro
bvdu
inhibit
concentr
time
greater
necessari
inhibit
declercq
et
al
preferenti
inhibit
may
due
differ
rate
virusassoci
kinas
catalyz
second
step
bvdu
phosphoryl
monoto
diphosph
fyfe
bvdu
found
nontox
effect
topic
treatment
experiment
herp
kerat
rabbit
maudgal
et
al
orofaci
herp
mice
park
et
al
cutan
herp
guineapig
freeman
et
al
oral
administr
use
human
treat
herp
zoster
declercq
et
al
druginduc
toxic
found
patient
studi
progress
lesion
format
arrest
within
hr
start
therapi
topic
treatment
ocular
hsv
vzv
infect
shown
effect
maudgal
et
al
fluoropyrimidin
fiac
fiau
fmau
inhibit
replic
cell
cultur
fiac
fmau
equal
activ
strain
potenc
acv
assay
rabbit
kidney
cell
declercq
et
al
trousdal
et
al
mechan
action
believ
similar
acv
triphosph
nucleotid
analog
bind
viru
dna
polymeras
may
act
chain
termin
viral
dna
replic
hsv
tkneg
mutant
mani
fold
less
suscept
inhibit
anim
studi
shown
fiau
fmau
activ
acv
treatment
hsv
enceph
mice
schinazi
et
al
rabbit
topic
applic
fiac
fmau
effect
treatment
eye
infect
trousdal
et
al
trousdal
et
al
guineapig
model
genit
hsv
infect
compar
fiac
fiau
fmau
acv
pfa
found
three
fluoropyrimidin
effect
either
acv
pfa
treatment
primari
genit
infect
fmau
effect
drug
test
human
fiac
report
therapeut
superior
araa
treatment
vzv
hsv
infect
immunosuppress
patient
compound
guanin
dhpg
also
known
acycl
nucleosid
structur
relat
acv
similar
mode
action
herp
group
virus
vitro
ashton
et
al
cheng
et
al
martin
et
al
vivo
mous
model
shown
dhpg
effect
acv
treatment
enceph
vagin
due
dhpg
also
effect
guineapig
model
primari
recrudesc
genit
herp
frasersmith
et
al
compar
acv
howev
dhpg
toxic
increas
activ
epsteinbarr
viru
cmv
increas
activ
cmv
make
dhpg
uniqu
although
variabl
report
degre
activ
cheng
et
al
smith
et
al
freita
et
al
shanley
et
al
dhpg
appear
effect
control
cmv
associ
retin
coliti
long
treatment
continu
masur
et
al
azidothymidin
yazidoydeoxythymidin
azt
nucleosid
analog
competit
inhibit
revers
transcriptas
hiv
cell
cultur
also
inhibit
infect
cytopath
effect
vitro
concentr
effect
block
vitro
infect
cpe
hiv
affect
vitro
immun
function
normal
human
tcell
mitsuya
et
al
clinic
trial
aid
arc
aidsrel
complex
patient
death
among
patient
receiv
placebo
one
death
among
patient
receiv
azt
also
appear
fewer
opportunist
infect
azt
group
fischl
et
ai
addit
trial
underway
anoth
studi
azt
treatment
associ
signific
decreas
hiv
core
antigen
serum
azt
treat
patient
compar
untreat
control
chaisson
et
al
result
azt
made
avail
investig
basi
aid
patient
pneumocysti
carinii
pneumonia
satisfi
certain
criteria
azt
also
excel
penetr
across
bloodbrain
barrier
hope
benefit
patient
hivassoci
neurolog
diseas
unfortun
bone
marrow
toxic
signific
problem
drug
sensit
test
clinic
isol
import
function
microbiolog
laboratori
essenti
administr
appropri
effect
drug
antivir
suscept
test
also
necessari
within
capabl
viru
laboratori
perform
standard
need
establish
two
method
commonli
use
laboratori
test
drug
sensit
given
viru
one
method
determin
viru
yield
liquid
cultur
medium
basic
done
ad
vari
concentr
drug
cultur
medium
virusinfect
cell
assay
aliquot
medium
yield
viru
result
reduct
viru
yield
plot
viru
yield
without
drug
second
perhap
simplest
method
antivir
assay
perform
routin
laboratori
plaqu
reduct
assay
plaqu
format
absenc
test
drug
compar
plaqu
format
presenc
drug
differ
concentr
fig
note
differ
result
obtain
differ
cell
cultur
system
use
plaqu
reduct
assay
illustr
fig
concentr
acv
necessari
inhibit
induc
plaqu
format
ce
cell
use
assay
wherea
um
drug
need
inhibit
amount
viru
gpe
cell
use
thu
import
select
cell
cultur
system
use
drug
sensit
test
appar
rapid
techniqu
nucleic
acid
hybrid
screen
gadler
et
al
autom
cpe
inhibit
assay
moran
et
al
appli
drug
sensit
test
significantli
facilit
eas
larg
number
antivir
agent
test
effect
viru
isol
practis
physician
absenc
specif
treatment
seem
littl
gain
diagnos
viral
diseas
howev
follow
reason
accur
viral
diagnosi
benefit
individu
patient
public
larg
although
treatment
avail
major
viral
ill
obtain
accur
diagnosi
still
import
implic
patient
manag
exact
etiolog
ill
known
unnecessari
often
uncomfort
diagnost
procedur
well
unwarr
antibiot
avoid
addit
physician
effect
manag
problem
may
aris
addit
aid
manag
acut
ill
accur
viral
diagnosi
allow
prognost
expect
cours
ill
describ
would
particularli
import
congenit
infect
rubella
cmv
genit
herp
simplex
infect
patient
contact
advis
risk
recurr
especi
relat
pregnanc
infect
newborn
well
increas
risk
cervic
cancer
genit
hpv
infect
detect
low
risk
high
risk
hpv
type
would
critic
determin
potenti
progress
cervic
cancer
certain
situat
prophylact
intervent
critic
pregnant
women
histori
genit
herp
infect
herp
waist
sexual
contact
genit
herp
monitor
frequent
cervicovagin
cultur
hsv
last
week
pregnanc
visintin
et
al
hsv
isol
week
prior
deliveri
caesarean
section
perform
within
hr
ruptur
membran
prevent
infect
fetu
knowledg
immun
statu
cmv
kidney
transplant
recipi
donor
critic
success
outcom
seroneg
recipi
receiv
kidney
seroposit
donor
signific
risk
contract
cmv
infect
reject
kidney
lopez
et
al
ho
et
al
passiv
immun
immunoglobulin
avail
certain
seriou
infect
hepat
contact
immunosuppress
children
expos
vzv
combin
vaccin
person
expos
rabi
amantadin
discuss
prevent
lessen
sever
infect
influenza
use
protect
unvaccin
high
risk
popul
describ
preced
section
specif
antivir
therapi
also
possibl
seriou
herp
infect
herp
simplex
enceph
neonat
infect
hsv
vzv
infect
compromis
host
acyclovir
adenin
arabinosid
hsv
kerat
treat
topic
idu
vidarabin
acv
tft
acyclovir
also
prove
benefit
treatment
genit
herp
infect
ribavirin
therapi
effect
treatment
lower
respiratori
rsv
infect
young
children
addit
newer
promis
drug
develop
nosocomi
viral
infect
import
caus
morbid
mortal
hospit
patient
best
prevent
accur
viral
diagnosi
obtain
medic
staff
educ
proper
precaut
prevent
spread
diseas
inhospit
transmiss
numer
viru
infect
document
includ
influenza
blumenfeld
et
al
respiratori
syncyti
hall
et
al
parainfluenza
mufson
et
al
enterovirus
gear
measroch
rotavirus
ryder
et
al
varicellazost
meyer
et
al
herp
simplex
linneman
et
al
hepat
virus
matthew
et
al
postic
et
al
rubella
carn
et
al
adenovirus
barret
al
newborn
infant
compromis
host
suffer
seriou
consequ
offend
agent
identifi
proper
precaut
institut
import
viral
diagnosi
public
health
long
recogn
illustr
control
hepat
arboviru
rabi
infect
major
impetu
behind
effect
vaccin
program
allow
continu
evalu
efficaci
current
vaccin
continu
surveil
particularli
import
determin
antigen
composit
influenza
vaccin
sinc
wit
discoveri
rotavirus
flewett
et
al
norwalk
agent
kapikian
et
al
jc
bk
papovavirus
padgett
et
al
gardner
et
al
delta
agent
rizzetto
et
al
recognit
nona
nonb
hepat
virus
account
major
transfus
associ
hepat
hoofnagl
et
al
dramat
discoveri
howev
hiv
etiolog
agent
aid
barresinoussi
et
al
gallo
et
al
levi
et
al
virus
implic
mani
well
known
diseas
paget
polymyos
chronic
neurolog
syndrom
autoimmun
diseas
diabet
cardiomyopathi
although
perhap
immedi
benefit
patient
enlarg
knowledg
understand
pathogenesi
spectrum
virusinduc
diseas
lead
improv
medic
care
futur
final
import
reason
obtain
accur
viral
diagnosi
educ
physician
lack
therapi
import
physician
well
vers
specif
mani
viral
diseas
adequ
diagnos
viral
syndrom
specif
diagnos
obtain
physician
stimul
learn
approach
age
chemotherapi
increas
clinic
acumen
physician
diagnos
viral
diseas
decidedli
import
sinc
discoveri
tissu
cultur
year
ago
mani
chang
occur
field
diagnost
virolog
interest
differ
viru
group
fluctuat
tremend
hsiung
signific
technolog
advanc
mani
new
virus
discov
hsiung
hiv
human
retrovirus
strike
exampl
noth
howev
greater
impact
diagnost
virolog
avail
effect
chemotherapi
recent
viru
laboratori
exist
either
part
health
depart
univers
research
laboratori
servic
readili
avail
commun
hospit
practis
physician
howev
next
decad
expect
progress
antivir
therapi
signific
chang
anticip
sinc
minim
amount
viru
may
present
clinic
sampl
transport
refer
laboratori
result
loss
infecti
viru
even
neg
find
facil
close
time
viru
isol
number
isol
optim
signific
number
specimen
process
cost
favor
affect
addit
commun
laboratori
physician
facilit
sever
recent
report
demonstr
feasibl
establish
satellit
mini
laboratori
herrmann
herrmann
peterson
et
al
laboratori
oper
small
scale
landri
hsiung
whose
servic
tailor
need
patient
popul
serv
highqual
commerci
reagent
becom
avail
mani
rapid
diagnost
method
continu
progress
area
anticip
near
futur
need
increas
becom
optimist
abil
interven
cours
viral
diseas
greater
need
obtain
accur
viral
diagnosi
evid
